Celltrion set to win EC approval for biosimilar to Humira medicine
Posted : 2020-12-11 12:41
Updated : 2020-12-11 17:18
Celltrion scientists work on a Humira biosimilar medicine at the company s research center in Songdo, Incheon. / Courtesy of Celltrion
By Kim Hyun-bin
Celltrion received a sales approval recommendation from the European Medicine Agency (EMA) for its CT-P17 drug, Thursday local time.
The recommendation came from the EMA s Committee for Human Medical Products (CHMP).
CHMP is an organization within the EMA that conducts scientific evaluation of a new medicine and submits an approval recommendation. This is practically considered a sales approval.
CT-P17 is a biosimilar of Humira and used to treat a range of illnesses, including rheumatoid arthritis. It will become the first of the high-level Humira biosimilar drugs to be introduced in the European market.